Published in J Clin Microbiol on January 01, 2004
Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent. J Clin Microbiol (2004) 1.58
A novel diagnostic target in the hepatitis C virus genome. PLoS Med (2009) 1.52
Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol (2006) 1.49
Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. J Clin Microbiol (2004) 1.16
Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology (2011) 1.02
Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. J Clin Microbiol (2004) 1.00
Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol (2009) 0.99
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology (2008) 0.91
Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus. J Clin Microbiol (2007) 0.87
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol (2012) 0.78
Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. PLoS One (2016) 0.76
Rational design of DNA sequences for nanotechnology, microarrays and molecular computers using Eulerian graphs. Nucleic Acids Res (2004) 0.76
Structure, stability and behaviour of nucleic acids in ionic liquids. Nucleic Acids Res (2014) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang (1999) 3.07
Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol (2000) 2.70
Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol (1996) 2.26
Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. J Clin Microbiol (1999) 1.68
Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol (2002) 1.31
Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology (1997) 1.17
Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 Assays for quantification of hepatitis C virus RNA in serum. J Clin Microbiol (2002) 1.15
Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J Clin Microbiol (2002) 1.14
Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2000) 1.05
Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol (1995) 1.02
Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol (2003) 1.00
Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol (2002) 0.97
Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol (1997) 0.90
Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group. Hepatology (1998) 0.90
Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis (2002) 0.89
Interferon treatment for chronic hepatitis C infection in hemophiliacs--influence of virus load, genotype, and liver pathology on response. Blood (1996) 0.88
Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy. Dig Dis Sci (1995) 0.86
Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother (1993) 0.85
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol (2009) 3.90
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 3.15
Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab (2004) 2.73
Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology (2006) 2.65
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology (2002) 2.55
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol (2007) 2.18
Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology (2006) 1.93
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. Clin Infect Dis (2006) 1.72
Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood (2004) 1.66
Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J Clin Microbiol (2003) 1.46
Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood (2006) 1.45
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol (2002) 1.30
Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol (2005) 1.27
Epidemiology and risk factors for hepatitis C in Alaska Natives. Hepatology (2004) 1.25
Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo. J Virol (2006) 1.23
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA (2007) 1.17
Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum (2004) 1.15
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Social structural and behavioral underpinnings of hyperendemic hepatitis C virus transmission in drug injectors. J Infect Dis (2006) 1.11
Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res (2004) 1.09
Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease. J Infect Dis (2007) 1.07
Dynamics of hepatitis C virus replication in human liver. Am J Pathol (2003) 1.05
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol (2010) 1.03
HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability. J Infect Dis (2006) 0.98
Current and future hepatitis C virus diagnostic testing: problems and advancements. Microbes Infect (2002) 0.96
Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics (2003) 0.96
Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. Br J Haematol (2006) 0.96
Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time. PLoS One (2011) 0.93
Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays. J Clin Microbiol (2005) 0.93
High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014. Emerg Infect Dis (2016) 0.93
Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol (2006) 0.93
Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C. Can J Gastroenterol (2010) 0.93
Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. Int J Circumpolar Health (2012) 0.92
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology (2008) 0.91
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology (2008) 0.89
Identification of a specific gene expression pattern associated with HCV-induced pathogenesis in HCV- and HCV/HIV-infected individuals. Virology (2006) 0.89
The normal menopause transition. Maturitas (2009) 0.89
Estimating the date of hepatitis C virus infection from patient interviews and antibody tests on stored sera. Am J Gastroenterol (2004) 0.89
Investigation of putative multisubtype hepatitis C virus infections in vivo by heteroduplex mobility analysis of core/envelope subgenomes. J Virol (2008) 0.84
Genetic and functional heterogeneity of the hepatitis C virus p7 ion channel during natural chronic infection. Virology (2011) 0.83
Comparison of different HCV viral load and genotyping assays. J Clin Virol (2003) 0.82
Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation. Virology (2010) 0.82
Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis. Virol J (2005) 0.81
Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. Am J Surg Pathol (2015) 0.81
Stability of human immunodeficiency virus type 1 proviral DNA in whole-blood samples. J Clin Microbiol (2005) 0.81
Hepatitis C and alcohol: fundamental and translational research directions. Alcohol Clin Exp Res (2003) 0.79
Ratio of two successive optical densities from the Roche HIV-1 monitor test as a measure of accuracy of estimates of human immunodeficiency virus RNA concentration. J Clin Microbiol (2002) 0.78
Steatosis and hepatitis C in an Alaska Native/American Indian population. Int J Circumpolar Health (2006) 0.78
Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection. J Infect Dis (2007) 0.77
High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infection. J Infect Dis (2006) 0.77
Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy. Clin Immunol (2003) 0.76